Cargando…
Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
Background: Currently, there are many different drugs to improve Alzheimer’s disease (AD) from different pathways. As a supplement and alternative medicine, traditional Chinese medicine (TCM) targets multiple pathways which may be different from classical Western medicine, which may be orchestrated...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471869/ https://www.ncbi.nlm.nih.gov/pubmed/36120381 http://dx.doi.org/10.3389/fphar.2022.956746 |
_version_ | 1784789178028916736 |
---|---|
author | Du, Xin-Yuan Cao, Yu-Shuang Yang, Juan Guo, Li-Chen Zhang, Tong Yuan, Qing Chen, Xi Hu, Li-min |
author_facet | Du, Xin-Yuan Cao, Yu-Shuang Yang, Juan Guo, Li-Chen Zhang, Tong Yuan, Qing Chen, Xi Hu, Li-min |
author_sort | Du, Xin-Yuan |
collection | PubMed |
description | Background: Currently, there are many different drugs to improve Alzheimer’s disease (AD) from different pathways. As a supplement and alternative medicine, traditional Chinese medicine (TCM) targets multiple pathways which may be different from classical Western medicine, which may be orchestrated with Western medicine to materialize multiplying efficacy in AD patients. Objective: To investigate the therapeutic effect and assess the available preclinical evidence and possible mechanisms of β-asarone which was extracted from Acorus gramineus Soland (Araceae, AGS) for AD based on rat and mouse animal models. Methods: PubMed, Embase, Scopus, Cochrane Library, BIOSIS Previews, Web of Science, EBSCO, and Google Scholar were searched from inception to 5 May 2022. Rat and mouse experiments assessing the therapeutic effects of β-asarone for AD were included. Primary outcomes were neuroethology, including escape latency and times of crossing platform. Second outcomes were cell apoptosis, including Bax and Bcl-2. The weighted mean difference (WMD) was generated for continuous variables. The relative outcomes were analyzed with the aid of Get Data Graph Digitizer 2.26 and software STATA version 16.0 MP. Results: For the primary endpoint, compared with the modeling group, β-asarone significantly decreased the escape latency (WMD = -12.61, 95% CI: -18.66 to -6.57) and increased the times of crossing platform (WMD = 1.50, 95% CI: 0.31–2.70). For the secondary endpoint, β-asarone remarkably reduced the relative expression of the amyloid precursor protein (APP) (WMD = −2.25, 95% CI: −2.49 to −2.01), decreased the expression of the apoptosis-related protein, associated X protein (Bax) (WMD = −2.40, 95% CI: −3.51 to −1.29), lowered the expression of apoptosis-related protein, B-cell lymphoma-2 (Bcl-2) (WMD = 0.42, 95% CI: 0.38–0.46), and decreased the signal pathway-related proteins, phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) (WMD = −0.70, 95% CI: −0.93 to −0.47) over the control group. Conclusion: β-asarone spectacularly improved the learning ability and memory in rats and mice, which might be correlated with its potential neuroprotective effect through multiple signaling pathways. |
format | Online Article Text |
id | pubmed-9471869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94718692022-09-15 Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis Du, Xin-Yuan Cao, Yu-Shuang Yang, Juan Guo, Li-Chen Zhang, Tong Yuan, Qing Chen, Xi Hu, Li-min Front Pharmacol Pharmacology Background: Currently, there are many different drugs to improve Alzheimer’s disease (AD) from different pathways. As a supplement and alternative medicine, traditional Chinese medicine (TCM) targets multiple pathways which may be different from classical Western medicine, which may be orchestrated with Western medicine to materialize multiplying efficacy in AD patients. Objective: To investigate the therapeutic effect and assess the available preclinical evidence and possible mechanisms of β-asarone which was extracted from Acorus gramineus Soland (Araceae, AGS) for AD based on rat and mouse animal models. Methods: PubMed, Embase, Scopus, Cochrane Library, BIOSIS Previews, Web of Science, EBSCO, and Google Scholar were searched from inception to 5 May 2022. Rat and mouse experiments assessing the therapeutic effects of β-asarone for AD were included. Primary outcomes were neuroethology, including escape latency and times of crossing platform. Second outcomes were cell apoptosis, including Bax and Bcl-2. The weighted mean difference (WMD) was generated for continuous variables. The relative outcomes were analyzed with the aid of Get Data Graph Digitizer 2.26 and software STATA version 16.0 MP. Results: For the primary endpoint, compared with the modeling group, β-asarone significantly decreased the escape latency (WMD = -12.61, 95% CI: -18.66 to -6.57) and increased the times of crossing platform (WMD = 1.50, 95% CI: 0.31–2.70). For the secondary endpoint, β-asarone remarkably reduced the relative expression of the amyloid precursor protein (APP) (WMD = −2.25, 95% CI: −2.49 to −2.01), decreased the expression of the apoptosis-related protein, associated X protein (Bax) (WMD = −2.40, 95% CI: −3.51 to −1.29), lowered the expression of apoptosis-related protein, B-cell lymphoma-2 (Bcl-2) (WMD = 0.42, 95% CI: 0.38–0.46), and decreased the signal pathway-related proteins, phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) (WMD = −0.70, 95% CI: −0.93 to −0.47) over the control group. Conclusion: β-asarone spectacularly improved the learning ability and memory in rats and mice, which might be correlated with its potential neuroprotective effect through multiple signaling pathways. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471869/ /pubmed/36120381 http://dx.doi.org/10.3389/fphar.2022.956746 Text en Copyright © 2022 Du, Cao, Yang, Guo, Zhang, Yuan, Chen and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Du, Xin-Yuan Cao, Yu-Shuang Yang, Juan Guo, Li-Chen Zhang, Tong Yuan, Qing Chen, Xi Hu, Li-min Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis |
title | Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis |
title_full | Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis |
title_fullStr | Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis |
title_full_unstemmed | Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis |
title_short | Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis |
title_sort | preclinical evidence and possible mechanisms of β-asarone for rats and mice with alzheimer’s disease: a systematic review and meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471869/ https://www.ncbi.nlm.nih.gov/pubmed/36120381 http://dx.doi.org/10.3389/fphar.2022.956746 |
work_keys_str_mv | AT duxinyuan preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT caoyushuang preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT yangjuan preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT guolichen preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT zhangtong preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT yuanqing preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT chenxi preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis AT hulimin preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis |